Literature DB >> 28430348

Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: a personal point of view.

Robert S Benjamin1.   

Abstract

Dr. Gianni Bonadonna is internationally recognized as one of the foremost medical oncologists of the 20th century. He is best known for his pioneering work in the development of adjuvant chemotherapy for breast cancer, but he was also the father of sarcoma chemotherapy. The first investigator to study the new chemotherapeutic agent adriamycin in the late 1960s, he noted activity against sarcomas. This article, focusing on adjuvant chemotherapy, adriamycin, and sarcomas, memorializes his achievements and their progeny.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28430348     DOI: 10.5301/tj.5000628

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  2 in total

1.  Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.

Authors:  Alessandro Gronchi; Nadia Hindi; Josefina Cruz; Jean-Yves Blay; Antonio Lopez-Pousa; Antoine Italiano; Rosa Alvarez; Antonio Gutierrez; Inmaculada Rincón; Claudia Sangalli; Jose Luis Pérez Aguiar; Jesús Romero; Carlo Morosi; Marie Pierre Sunyach; Roberta Sanfilippo; Cleofe Romagosa; Dominique Ranchere-Vince; Angelo P Dei Tos; Paolo G Casali; Javier Martin-Broto
Journal:  EClinicalMedicine       Date:  2019-03-11

2.  Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.

Authors:  Thomas Filleron; Sophie Le Guellec; Christine Chevreau; Bastien Cabarrou; Tom Lesluyes; Sabrina Lodin; Angélique Massoubre; Muriel Mounier; Muriel Poublanc; Frédéric Chibon; Thibaud Valentin
Journal:  BMC Cancer       Date:  2020-07-31       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.